The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies

Guangming Tian, Xinliang Zhao, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Di Wu, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Jian Fang